Reporting from:
– Annual Meeting of the American Society of Hematology, December 4-7, 2004, San Diego
– Chemotherapy Foundation Symposium, November 10-13 2004, New York
– European Society for Medical Oncology Congress, October 29-November 2, 2004, Vienna
– Journal of Clinical Oncology
– New England Journal of Medicine
In this edition:
At the ASH conference in San Diego, Owen O’Connor described his investigation involving heavily pretreated patients with mantle cell lymphoma whose disease responded to bortezomib. George Canellos discussed the clinical implications.
Rituximab-CHOP combination therapy markedly improved outcomes for low-risk, younger patients with diffuse large B-cell lymphoma, according to study results announced by Michael Pfreundschuh.
The oral 5-FU pro-drug capecitabine has performed as well as intravenous therapy, according to Chris Twelves, who presented findings to the Chemotherapy Foundation in New York.
The older drug hydroxyurea was just as effective and caused fewer complications than its molecularly targeted modern replacement, anagrelide, for treating patients with essential thrombocythemia, according to Tony Green,who spoke in San Diego.
